Fevipiprant

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

AsthmaHepatic Impairment

Phase 1

Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects

CompletedNCT03048448

Novartis PharmaceuticalsHepatic Impairment

Start: 2017-05-31End: 2019-04-22Updated: 2020-12-11

Phase 2

Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma

TerminatedNCT03650400

Novartis PharmaceuticalsAsthma

Start: 2019-05-01End: 2020-01-22Updated: 2026-01-13